To commercialize its multi-faceted tissue repair technology, TISSIUM is relying on a business model that will see it develop and commercialize some applications on its own and others in collaboration with larger, well-established partners. Excerpted from MedTech Strategist's recent feature on TISSIUM.
Trial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
FDA’s first-ever ejection of a third-party reviewer. Excerpted from Pathways’ Picks, August 18, 2021
Discover the opportunities and challenges that impact the global medtech regulatory and reimbursement community with MedTech Strategist Market Pathways.Subscribe Free Premier Issue Learn More
Digital health investment is now at an all-time high, according to Rock Health’s most recent report on H1 2021 funding trends. Excerpted from MedTech Strategist's recent feature, "Digital Health Deals Soar in First Half of 2021."
Discover the people, technologies, and companies in the global medical device industry that will impact your corporate strategy with MedTech Strategist.Subscribe Now Learn More
The National Medical Products Administration updated its policies and issued a draft guidance on designation and submissions of single-entity drug-device combination products. Importantly, NMPA made its submission requirements more flexible. Excerpted from Pathways’ Picks July 27.